TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Orexo AB ( (SE:ORX) ) is now available.
Orexo AB announced positive results from a preclinical study using its AmorphOX technology to develop a powder-based intranasal formulation of semaglutide, a GLP-1 receptor agonist. The study showed that the intranasal formulations achieved significantly higher plasma concentrations and bioavailability compared to oral tablets, suggesting potential for needle-free delivery and improved patient adherence. This advancement could enhance Orexo’s strategic positioning by enabling partnerships to expand the use of this novel delivery method for more efficient treatment options.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK21.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
More about Orexo AB
Orexo is a Swedish pharmaceutical company with 30 years of experience in developing improved pharmaceuticals using proprietary formulation technologies. The company focuses on providing innovative treatment solutions for opioid use disorder in the US market and collaborates with leading partners to develop products for other therapeutic areas globally. Orexo is listed on Nasdaq Stockholm and the OTCQX market in the US.
Average Trading Volume: 24,052
Technical Sentiment Signal: Buy
Current Market Cap: SEK689.3M
For a thorough assessment of ORX stock, go to TipRanks’ Stock Analysis page.